Phase I/IIa Systemic Gene Delivery Clinical Trial of scAAV9.U7.ACCA for Exon 2 Duplication-Associated Duchenne Muscular Dystrophy
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Number of Participants With Unacceptable Toxicity.
研究概览
简要总结
Open-label, single dose clinical trial of scAAV9.U7.ACCA via peripheral limb vein injection for Duchenne muscular dystrophy boys who have a duplication of exon 2.
详细描述
The proposed clinical trial is a systemic (intravenous) delivery of scAAV9.U7.ACCA for DMD patients with a duplication of exon 2 in the DMD gene. Preclinical data shows that the small nuclear RNA (snRNA) construct delivered by the scAAV9.U7.ACCA vector causes significant skipping of exon 2, resulting in exclusion of the exon from the mature messenger RNA (mRNA) with a high degree of efficiency, leading to mRNA containing only a single exon 2 (wild type [WT] mRNA) or no copies of exon 2 (Del2 mRNA). Translation of the wild-type mRNA results in entirely normal dystrophin protein, whereas translation of the Del2 mRNA via translational initiation of an internal ribosome entry sequence, or IRES) results in a highly functional isoform expressed in patients known to walk into their eighth decade.
The study is designed as an open-label trial to assess safety and obtain preliminary efficacy data. scAAV9.U7.ACCA will be delivered to the systemic circulation via peripheral limb vein.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 13 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age greater than 6 months and less than 14 years
- •Confirmed duplication of exon 2 in the DMD gene using a clinically accepted technique that completely defines the mutation
- •Pre-ambulant (not yet walking) or ambulant (as defined by the ability to walk 10 meters without assistance)
- •Males of any ethnic group will be eligible
- •Ability to cooperate with muscle testing
- •In subjects age 4 and above, stable dose and regimen of corticosteroid therapy (prednisone, deflazacort, or their generic forms) for at least 12 weeks prior to gene transfer.
排除标准
- •Active viral infection based on clinical observations
- •Symptoms or signs of cardiomyopathy, including:
- •Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
- •Echocardiogram with ejection fraction below 40%
- •Serological evidence of HIV infection, or Hepatitis B or C infection
- •Diagnosis of (or ongoing treatment for) an autoimmune disease
- •Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
- •Concomitant illness or requirement for chronic drug treatment that in the opinion of the SI creates unnecessary risks for gene transfer
- •AAV9 binding antibody titers ≥ 1:400 as determined by ELISA immunoassay
- •Abnormal laboratory values in the clinically significant range as listed in Table 7, based upon normal values in the Nationwide Children's Hospital Laboratory.
研究组 & 干预措施
Cohort 1 (Minimal Efficacious Dose)
The Minimal Effective Dose (MED) will be delivered.
干预措施: scAAV9.U7.ACCA (Biological)
结局指标
主要结局
Number of Participants With Unacceptable Toxicity.
时间窗: 2 years
Unacceptable toxicity is defined as the occurrence of two or more unexpected Grade III or higher treatment-related toxicities, as defined by CTCAE 5.0.
次要结局
- Change in Dystrophin Expression From Baseline Following Treatment With scAAV9.U7.ACCA.(1 year)
- Changes in Percent of Exon 2 Skipping/Exclusion in the Dystrophin mRNA Transcript.(1 year)
研究者
Megan Waldrop
Professor of Neurology
Nationwide Children's Hospital